Merck & Company Inc (MRK)vsRallybio Corp (RLYB)
MRK
Merck & Company Inc
$144.85
+0.64%
HEALTHCARE · Cap: $355.10B
RLYB
Rallybio Corp
$16.88
+0.75%
HEALTHCARE · Cap: $89.88M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 10304699% more annual revenue ($66.57B vs $646,000). RLYB leads profitability with a 7051.0% profit margin vs 4.8%. RLYB trades at a lower P/E of 2.1x. RLYB earns a higher WallStSmart Score of 49/100 (D+).
MRK
Hold36
out of 100
Grade: F
RLYB
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$144.85
$62.01 premium
Intrinsic value data unavailable for RLYB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 7051 of every $100 in revenue as profit
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -15.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : RLYB
The strongest argument for RLYB centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 7051.0% and operating margin at -3935.0%.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : RLYB
The primary concerns for RLYB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRK carries more volatility with a beta of 0.23 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RLYB scores higher overall (49/100 vs 36/100), backed by strong 7051.0% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Rallybio Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Rallybio Corp is a clinical-stage biotechnology company focused on developing innovative therapies for rare diseases, especially within immunology and hematology. The company boasts a promising pipeline of biologic drug candidates that are currently advancing through clinical trials, backed by an experienced management team with significant industry expertise. By forming strategic partnerships, Rallybio enhances its capacity to deliver transformative treatments in underserved therapeutic areas, demonstrating its commitment to improving patient outcomes. With a well-defined strategy and a robust developmental framework, Rallybio is strategically positioned to achieve significant milestones in the healthcare sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?